AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and BioConnection, a specialized contract manufacturing organization (CMO) focusing on aseptic filling of vials and syringes for clinical and commercial production, today announced a new strategic partnership. The companies are partnering to provide end-to-end biopharmaceutical development and manufacturing capabilities for drug substance and drug product using the development and manufacturing expertise of AGC Biologics and the specialized aseptic filling capabilities of BioConnection.

The new partnership offers a seamless, full-service clinical-stage development and manufacturing solution that accelerates timelines and brings life-saving therapies to market more efficiently. By combining world-class drug substance and drug product services, AGC Biologics together with BioConnection now offer one convenient “gene to vial” value chain service with a single contract and project management team for the project lifecycle. Further, developers will save time and resources by avoiding long, complex processes associated with negotiating a separate drug substance and drug product contract and be able to conveniently plan drug filling activities for as soon as their substance release is scheduled – all through this new offering.